Bristol-Myers Squibb
Q2 2026, reported July 30, delivered revenue of $13.0B (+6%), with the Growth Portfolio at $7.6B (+15%) and the Legacy Portfolio at $5.4B (-4%); non-GAAP EPS was $2.04 and full-year guidance rose to $49.0-50.0B revenue and $6.75-7.00 non-GAAP EPS. Eliquis drove the raise rather than eroding — $4.48B in the quarter (+22%), with full-year growth guided to 20-25% — though management expects a $1.5-2B Eliquis step-down in 2027 on European patent expiry, ahead of US loss of exclusivity in April 2028. The pipeline calendar slipped — the milvexian atrial-fibrillation readout moved to Q1 2027 and the Cobenfy ADEPT Alzheimer's-psychosis readouts to early 2027, while Cobenfy sold only $63M in the quarter; mezigdomide is filed with a May 2027 PDUFA. AI is an operating-model bet rather than a pipeline source — Claude deployed to 30,000+ employees under the May 2026 Anthropic agreement and an expanded NVIDIA collaboration (July 2026) on Vera Rubin NVL72 infrastructure for predictive modeling. None of the late-stage assets was AI-discovered.
Scenarios
The Growth Portfolio (+15% to $7.6B in Q2) plus an Eliquis windfall buys time before the 2028 cliff. Mezigdomide is filed, and if milvexian (AF readout Q1 2027) and Cobenfy in Alzheimer's psychosis (early 2027) succeed, replacement revenue arrives roughly as Eliquis and Opdivo decline. Enterprise Claude plus NVIDIA compute could compress discovery and trial cycle times and lower the cost per approved drug.
The cliff is intact and the bridge is wobbling — Eliquis is guided to step down $1.5-2B in 2027 and loses US exclusivity in April 2028, Opdivo is already declining (-3% in Q2) ahead of its 2028 US loss of exclusivity, and two of the most important readouts slipped into 2027. Cobenfy at $63M a quarter is far below launch expectations. The AI program is infrastructure and productivity, and no AI-discovered candidate is in Phase III, so AI cannot close the 2028 gap.
Key Factors to Watch
- ●Q2 2026 (Jul 30) — revenue $13.0B (+6%), Growth Portfolio $7.6B (+15%), FY26 guide raised to $49-50B revenue and $6.75-7.00 non-GAAP EPS
- ●Eliquis $4.48B (+22%) in Q2 but guided to step down $1.5-2B in 2027; US loss of exclusivity April 2028
- ●Milvexian AF readout slipped to Q1 2027 and Cobenfy ADEPT to early 2027 — Cobenfy Q2 sales only $63M
- ●Anthropic Claude enterprise deployment (May 2026) and NVIDIA Vera Rubin NVL72 expansion (Jul 2026) — AI is operating infrastructure, no AI-discovered Phase III asset
Score History
| Date | Score | Direction | Note |
|---|---|---|---|
| 2026-10-10 | 5.8 | Neutral | W41 rotation refresh — score holds 5.8, no dim change. Rebased on Q2 2026 8-K (Jul 30) — revenue $13.0B, Eliquis $4.48B +22%, FY guide $49-50B. Fixed errors — Eliquis is growing, not eroding faster than modeled; removed wrong $12-15B combined LOE figure and unverified Opdivo EU June 2028 date; milvexian AF and ADEPT readouts now 2027. Added NVIDIA Jul 2026 expansion (pre-Aug 22, not scored). |
| 2026-06-21 | 5.8 | Neutral | W25: Score 5.7→5.8 (aam 6→7). Strategic agreement with Anthropic (May 20) deploys Claude Enterprise as a shared agentic platform across 30,000+ employees in R&D, clinical development, manufacturing and commercial — a C-suite-sanctioned, enterprise-wide commitment that moves adoption from Fast Follower toward Active Adopter. The LOE cliff and the absence of a Phase III AI-discovered candidate keep the score neutral. |
| 2026-03-08 | 5.7 | Neutral | Score 5.8→5.7 (formula reweight: sb 0.25→0.15, are 0.20→0.25, md 0.20→0.25, dr 0.20→0.25, aam 0.15→0.10) |
| 2026-03-08 | 5.8 | Neutral | Score 6.6->5.8 (are 7->5, dr 5->6, aam 7->6). External research cross-ref: 64% of 2025 revenue faces LOE by decade end, partnership-dependent AI strategy more replicable, Fast Follower maturity without C-suite AI leadership |
| 2026-03-08 | 6.6 | Positive | Initial assessment from batch 3 research |
Healthcare Peers
Last researched: 2026-10-10
This is research and analysis, not financial advice. Scores reflect AI impact potential, not investment recommendations.